Delenex Therapeutics AG
Records under this name other than patents Delenex Therapeutics AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 10 of 10 · Back to Delenex Therapeutics AG
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,404,930 | Antibody to Human IL-1 Beta Formerly held In force · High confidence | In force | High confidence | |
| US 10,077,302 | Method of Inhibiting Human IL-1 Beta by Administering an Antibody to Human IL-1 Beta Formerly held Lapsed on the fee record Ended Sep 18, 2026 · High confidence | Lapsed on the fee record | Ended Sep 18, 2026 | High confidence |
| US 11,407,824 | Nucleic Acids Encoding Antibodies Against IL-1 Beta Formerly held Lapsed on the fee record Ended Aug 9, 2026 · High confidence | Lapsed on the fee record | Ended Aug 9, 2026 | High confidence |
| US 9,914,772 | Antibodies Against IL-1 Beta Formerly held Lapsed on the fee record Ended Mar 13, 2026 · High confidence | Lapsed on the fee record | Ended Mar 13, 2026 | High confidence |
| US 7,902,340 | Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK Formerly held Lapsed on the fee record Ended Mar 8, 2023 · USPTO record | Lapsed on the fee record | Ended Mar 8, 2023 | USPTO record |
| US 8,945,563 | Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK Formerly held Lapsed on the fee record Ended Feb 3, 2023 · USPTO record | Lapsed on the fee record | Ended Feb 3, 2023 | USPTO record |
| US 9,512,411 | Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK Formerly held Lapsed on the fee record Ended Dec 6, 2020 · USPTO record | Lapsed on the fee record | Ended Dec 6, 2020 | USPTO record |
| US 9,273,126 | Humanized antibodies against the beta-amyloid peptide Formerly held Lapsed on the fee record Ended Mar 1, 2020 · USPTO record | Lapsed on the fee record | Ended Mar 1, 2020 | USPTO record |
| US 8,323,647 | Humanized antibodies against the β-amyloid peptide Formerly held Lapsed on the fee record Ended Dec 4, 2016 · USPTO record | Lapsed on the fee record | Ended Dec 4, 2016 | USPTO record |
| US 6,821,728 | Screening System Formerly held Lapsed on the fee record Ended Nov 23, 2016 · High confidence | Lapsed on the fee record | Ended Nov 23, 2016 | High confidence |